Pharming Group N.V.

What they do

Pharming develops and commercializes protein replacement therapies and precision medicines for rare diseases. Its commercial portfolio consists of RUCONEST (recombinant C1 esterase inhibitor) for hereditary angioedema and Joenja (leniolisib) for APDS. The company operates through subsidiaries in the United States, Europe, and Australia, and is advancing additional pipeline assets including KONFIDENT, an oral plasma kallikrein inhibitor candidate.

Revenue drivers

• RUCONEST — Recombinant C1 esterase inhibitor for hereditary angioedema, marketed in the U.S. and Europe. Revenue is generated through direct sales and distributors, and it is the larger of the two commercial products.
• Joenja — Leniolisib, an oral PI3K delta inhibitor approved for activated phosphoinositide 3-kinase delta syndrome (APDS) in the U.S. Revenue comes from U.S. sales, with European launch underway.
• Geographic revenue mix — The company reports revenue by geographic region, with the United States representing the largest market, followed by Europe and the rest of the world.
• Pipeline and licensing — Pharming has licensed assets such as KL1333 and has an investment in Isomerase Therapeutics through its subsidiary Abliva AB. These are not yet revenue-generating.

Recent performance

The source excerpts do not provide specific revenue, net income, or cash flow figures for the latest fiscal year or periods. Therefore, no quantitative performance data can be reported here.

Strategy

Pharming's stated strategy centers on expanding its commercial portfolio, advancing its pipeline, and pursuing business development. The company completed the acquisition of Abliva AB in 2025 and licensed KL1333 in June 2025. It also holds an investment in Isomerase Therapeutics. These moves indicate a focus on rare disease assets and diversification beyond its existing commercial products.

Risks

• Revenue concentration — Sales of RUCONEST and Joenja account for substantially all revenue, and the loss of either product would significantly impair the business.
• Customer concentration — A small number of customers, including distributors and specialty pharmacies, represent a significant portion of revenue, creating dependence on their continued purchases.
• Regulatory and clinical risk — Pipeline candidates such as KONFIDENT and KL1333 face uncertainties inherent in clinical development, including trial outcomes and regulatory approvals.
• Foreign exchange risk — With operations in multiple countries, Pharming's results are exposed to fluctuations in EUR/USD, GBP/USD, and other currency pairs affecting revenue and expenses.

Outlook

The source excerpts do not include management's specific forward-looking guidance or outlook statements for future periods. Therefore, no outlook can be summarized.